Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
AMG 133 For Obesity Is One To Watch In CV Portfolio
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
You may also be interested in...
Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity
The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.